Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Solute carrier family 22 member 14 (SLC22A14)
- Target
- SLC22A14
- Molecular classification
- Transporter, Organic cation/anion transporter, Solute carrier (SLC) protein family, Transmembrane protein
01
Overview
Solute carrier family 22 member 14 (SLC22A14) is a transmembrane transporter protein, highly expressed in testicular tissue and localized particularly to the mitochondrial membrane of sperm cells. Its principal function is the transport of riboflavin, a vital precursor for energy metabolism via flavoenzymes critical for oxidative phosphorylation and fatty acid β-oxidation in sperm. Deficiency or loss of function of SLC22A14 disrupts sperm motility and flagellar structure, resulting in severe male infertility. The protein is a member of the broader SLC22 organic cation/anion transporter family, sharing structural and functional similarities with other family members. While highly conserved and physiologically important in mammals, it currently lacks approved therapeutic modulators but is of interest for male contraceptive strategies due to its spermatogenesis-specific activity.
- Other names
- SLC22A14Organic cation transporter-like 4 (ORCTL4, ORCTL-4)OCTL2OCTL4Solute carrier family 22 (organic cation transporter), member 14
02
Mechanism of action
SLC22A14 provides transmembrane transport of riboflavin into sperm mitochondria; inhibition would suppress sperm oxidative phosphorylation and motility, potentially rendering sperm non-functional. No approved drug mechanisms on SLC22A14 are known.
03
Biological functions
Riboflavin (vitamin B2) transmembrane transportOrganic cation/anion transportSperm motilitySperm flagellar structure maintenanceEnergy metabolism (required for oxidative phosphorylation and fatty acid β-oxidation in sperm)
04
Disease associations
Male infertility (deficiency causes defects in sperm motility and structure, leading to infertility)Associated with Brugada Syndrome and Benign Epilepsy With Centrotemporal Spikes (genetic association only, mechanistic link not established)
05
Safety considerations
Targeting SLC22A14 for male contraception may result in complete and potentially irreversible male infertility if not carefully managedSpecific safety and off-target issues not documented due to lack of existing drugs
06
Biomarkers
Decreased SLC22A14 expression in sperm correlates with idiopathic asthenospermia (reduced sperm motility) and infertilityPotential candidate biomarker for male fertility assessment
Beyond the preview
Go deeper on Solute carrier family 22 member 14 (SLC22A14).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Solute carrier family 22 member 14 (SLC22A14).